Loading clinical trials...

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

NCT02878603•Sanofi

View on ClinicalTrials.gov

Summary

The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Completed the Final (28 day) follow-up visit in Study ALX0681-C301.
•2. \>= 18 years of age at the time of signing the informed consent form.
•3. Provided informed consent prior to initiation of any study specific activity/procedure.

Exclusion Criteria

•1. Not being able/willing to comply with the study protocol procedures.
•2. Currently enrolled in a clinical study with another investigational drug or device.

Locations (45)

Investigator site

St Louis, Missouri, United States

Investigator site

Valhalla, New York, United States

Investigator Site

Durham, North Carolina, United States

Investigator Site

Columbus, Ohio, United States

Investigator Site

Oklahoma City, Oklahoma, United States

Investigator site

Pittsburgh, Pennsylvania, United States

Investigator Site

Charleston, South Carolina, United States

Investigator site

Greenville, South Carolina, United States

Investigator site

Vienna, Austria

Investigator site

Antwerp, Belgium

Key Dates

Start Date

October 6, 2016

Primary Completion Date

October 23, 2020

Completion Date

October 23, 2020

Last Updated

March 28, 2022

Enrollment

104

ACTUAL participants

Conditions

Acquired Thrombotic Thrombocytopenic Purpura

Interventions

Caplacizumab

BIOLOGICAL

Standard of Care

OTHER

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

NCT02553317

Acquired Thrombotic Thrombocytopenic Purpura

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 28, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions